The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition.
 
Katherine M. Bever
Employment - Personal Genome Diagnostics (I); Personal Genome Diagnostics (I); Personal Genome Diagnostics (I); Personal Genome Diagnostics (I); Qiagen (I); Qiagen (I); Qiagen (I); Qiagen (I)
 
Hao Wang
No Relationships to Disclose
 
Jennifer N. Durham
Employment - AstraZeneca/MedImmune (I); AstraZeneca/MedImmune (I); AstraZeneca/MedImmune (I); AstraZeneca/MedImmune (I)
Stock and Other Ownership Interests - AstraZeneca/MedImmune (I); AstraZeneca/MedImmune (I); AstraZeneca/MedImmune (I); AstraZeneca/MedImmune (I)
 
Susan Petrie
No Relationships to Disclose
 
Jessica Hoare
No Relationships to Disclose
 
Cara Wilt
No Relationships to Disclose
 
William Howard Sharfman
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Regeneron; Regeneron; Regeneron; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis
 
Nilofer Saba Azad
Honoraria - AMAG Pharmaceuticals; AMAG Pharmaceuticals; AMAG Pharmaceuticals; AMAG Pharmaceuticals
Consulting or Advisory Role - AMAG Pharmaceuticals; AMAG Pharmaceuticals; AMAG Pharmaceuticals; AMAG Pharmaceuticals; Dava Oncology; Dava Oncology; Dava Oncology; Dava Oncology; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); Astex Pharmaceuticals (Inst); Astex Pharmaceuticals (Inst); Astex Pharmaceuticals (Inst); Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Incyte; Incyte; Incyte; Incyte; Intensity Therapeutics (Inst); Intensity Therapeutics (Inst); Intensity Therapeutics (Inst); Intensity Therapeutics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst)
 
Daniel A. Laheru
No Relationships to Disclose
 
Robert A Anders
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck
 
Drew M. Pardoll
Stock and Other Ownership Interests - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Compugen; Compugen; Compugen; Compugen; Neximmune; Neximmune; Neximmune; Neximmune
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Medimmune; Medimmune; Medimmune; Medimmune; Merck; Merck; Merck; Merck; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi
Research Funding - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Compugen; Compugen; Compugen; Compugen; Potenza Therapeutics; Potenza Therapeutics; Potenza Therapeutics; Potenza Therapeutics
Patents, Royalties, Other Intellectual Property - Royalties on patents licensed to Aduro, BMS, Potenza; Royalties on patents licensed to Aduro, BMS, Potenza; Royalties on patents licensed to Aduro, BMS, Potenza; Royalties on patents licensed to Aduro, BMS, Potenza
 
Suzanne Louise Topalian
Stock and Other Ownership Interests - Aduro Biotech (I); Aduro Biotech (I); Aduro Biotech (I); Aduro Biotech (I); Compugen (I); Compugen (I); Compugen (I); Compugen (I); DNAtrix (I); DNAtrix (I); DNAtrix (I); DNAtrix (I); Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; ERVAXX (I); ERVAXX (I); ERVAXX (I); ERVAXX (I); Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; FLX Bio (I); FLX Bio (I); FLX Bio (I); FLX Bio (I); Jounce Therapeutics (I); Jounce Therapeutics (I); Jounce Therapeutics (I); Jounce Therapeutics (I); Potenza Therapeutics (I); Potenza Therapeutics (I); Potenza Therapeutics (I); Potenza Therapeutics (I); Tizona Therapeutics, Inc. (I); Tizona Therapeutics, Inc. (I); Tizona Therapeutics, Inc. (I); Tizona Therapeutics, Inc. (I); WindMIL (I); WindMIL (I); WindMIL (I); WindMIL (I)
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Amgen (I); Amgen (I); Amgen (I); Amgen (I); Bayer (I); Bayer (I); Bayer (I); Bayer (I); Compugen (I); Compugen (I); Compugen (I); Compugen (I); DNAtrix (I); DNAtrix (I); DNAtrix (I); DNAtrix (I); Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Dynavax Technologies (I); Dynavax Technologies (I); Dynavax Technologies (I); Dynavax Technologies (I); ERVAXX (I); ERVAXX (I); ERVAXX (I); ERVAXX (I); Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; FLX Bio (I); FLX Bio (I); FLX Bio (I); FLX Bio (I); Immunomic Therapeutics (I); Immunomic Therapeutics (I); Immunomic Therapeutics (I); Immunomic Therapeutics (I); Janssen Oncology (I); Janssen Oncology (I); Janssen Oncology (I); Janssen Oncology (I); MedImmune (I); MedImmune (I); MedImmune (I); MedImmune (I); Merck; Merck; Merck; Merck; Tizona Therapeutics, Inc. (I); Tizona Therapeutics, Inc. (I); Tizona Therapeutics, Inc. (I); Tizona Therapeutics, Inc. (I); WindMIL (I); WindMIL (I); WindMIL (I); WindMIL (I)
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Compugen (I); Compugen (I); Compugen (I); Compugen (I); Potenza Therapeutics (I); Potenza Therapeutics (I); Potenza Therapeutics (I); Potenza Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Aduro Biotech (I); Aduro Biotech (I); Aduro Biotech (I); Aduro Biotech (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Immunonomic Therapeutics (I); Immunonomic Therapeutics (I); Immunonomic Therapeutics (I); Immunonomic Therapeutics (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics
 
Elizabeth M. Jaffee
Consulting or Advisory Role - Adaptive Biotechnologies; Adaptive Biotechnologies; Adaptive Biotechnologies; Adaptive Biotechnologies; CStone Pharmaceuticals; CStone Pharmaceuticals; CStone Pharmaceuticals; CStone Pharmaceuticals; Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Genocea Biosciences; Genocea Biosciences; Genocea Biosciences; Genocea Biosciences; Incyte; Incyte; Incyte; Incyte
Research Funding - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Corvus Pharmaceuticals; Corvus Pharmaceuticals; Corvus Pharmaceuticals; Corvus Pharmaceuticals
Patents, Royalties, Other Intellectual Property - I developed GVAX which is being tested in the clinics. It was licensed to Adoro Biotech. IF it becomes commercial I will have the potential to receive royalties. Also, I have received milestone payments yearly.; I developed GVAX which is being tested in the clinics. It was licensed to Adoro Biotech. IF it becomes commercial I will have the potential to receive royalties. Also, I have received milestone payments yearly.; I developed GVAX which is being tested in the clinics. It was licensed to Adoro Biotech. IF it becomes commercial I will have the potential to receive royalties. Also, I have received milestone payments yearly.; I developed GVAX which is being tested in the clinics. It was licensed to Adoro Biotech. IF it becomes commercial I will have the potential to receive royalties. Also, I have received milestone payments yearly.
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genocea Biosciences; Genocea Biosciences; Genocea Biosciences; Genocea Biosciences; MedImmune; MedImmune; MedImmune; MedImmune
Other Relationship - Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics
 
Dung T. Le
Honoraria - Merck; Merck; Merck; Merck
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck
Research Funding - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Curegenix; Curegenix; Curegenix; Curegenix; Medivir; Medivir; Medivir; Medivir; Merck; Merck; Merck; Merck
Patents, Royalties, Other Intellectual Property - Inventor of technology, "Microsatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition".; Inventor of technology, "Microsatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition".; Inventor of technology, "Microsatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition".; Inventor of technology, "Microsatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition".